Daiichi Sankyo in pursuit of Novartis’ Rydapt with next-generation FLT3 drug

Novartis’ FLT3 inhibitor Rydapt was a much-welcomed addition to the armamentarium against acute myeloid leukemia when it was approved last year. Now, Daiichi Sankyo has data that could allow it to file its new-generation rival for approval.